CN1543959A - Galantamin sustained release preparation and preparing process - Google Patents
Galantamin sustained release preparation and preparing process Download PDFInfo
- Publication number
- CN1543959A CN1543959A CNA2003101157204A CN200310115720A CN1543959A CN 1543959 A CN1543959 A CN 1543959A CN A2003101157204 A CNA2003101157204 A CN A2003101157204A CN 200310115720 A CN200310115720 A CN 200310115720A CN 1543959 A CN1543959 A CN 1543959A
- Authority
- CN
- China
- Prior art keywords
- agent
- slow releasing
- releasing preparation
- galantamine
- lactose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 title claims description 71
- 229960003980 galantamine Drugs 0.000 title claims description 40
- 238000000034 method Methods 0.000 title description 4
- 239000003405 delayed action preparation Substances 0.000 title description 2
- 238000002360 preparation method Methods 0.000 claims abstract description 45
- 239000003814 drug Substances 0.000 claims abstract description 13
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 12
- 239000008101 lactose Substances 0.000 claims abstract description 12
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 12
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 12
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 12
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229920001661 Chitosan Polymers 0.000 claims abstract description 6
- 229920002472 Starch Polymers 0.000 claims abstract description 6
- 235000019698 starch Nutrition 0.000 claims abstract description 6
- 239000008107 starch Substances 0.000 claims abstract description 6
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims abstract description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims abstract description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims abstract description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims abstract description 3
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 3
- 235000021355 Stearic acid Nutrition 0.000 claims abstract description 3
- 229940072056 alginate Drugs 0.000 claims abstract description 3
- 235000010443 alginic acid Nutrition 0.000 claims abstract description 3
- 229920000615 alginic acid Polymers 0.000 claims abstract description 3
- 229960001631 carbomer Drugs 0.000 claims abstract description 3
- 239000004203 carnauba wax Substances 0.000 claims abstract description 3
- 229920002678 cellulose Polymers 0.000 claims abstract description 3
- 239000001913 cellulose Substances 0.000 claims abstract description 3
- 235000010980 cellulose Nutrition 0.000 claims abstract description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims abstract description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims abstract description 3
- 229940075507 glyceryl monostearate Drugs 0.000 claims abstract description 3
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims abstract description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims abstract description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims abstract description 3
- 239000008117 stearic acid Substances 0.000 claims abstract description 3
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims description 31
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 9
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 9
- 238000013268 sustained release Methods 0.000 claims description 8
- 239000012730 sustained-release form Substances 0.000 claims description 8
- 229920000881 Modified starch Polymers 0.000 claims description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 7
- 229960003943 hypromellose Drugs 0.000 claims description 7
- 239000011159 matrix material Substances 0.000 claims description 7
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 4
- 241001597008 Nomeidae Species 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- -1 hydroxypropyl Chemical group 0.000 claims description 4
- 239000000661 sodium alginate Substances 0.000 claims description 4
- 235000010413 sodium alginate Nutrition 0.000 claims description 4
- 229940005550 sodium alginate Drugs 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 2
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 3
- 210000000653 nervous system Anatomy 0.000 abstract description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 abstract 1
- 235000013869 carnauba wax Nutrition 0.000 abstract 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 12
- 239000003826 tablet Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 208000024827 Alzheimer disease Diseases 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- GXFZCDMWGMFGFL-KKXMJGKMSA-N (+)-Tubocurarine chloride hydrochloride Chemical compound [Cl-].[Cl-].C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CC[NH+]3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 GXFZCDMWGMFGFL-KKXMJGKMSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 1
- 241001111317 Chondrodendron tomentosum Species 0.000 description 1
- 239000008709 Curare Substances 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 241000234271 Galanthus Species 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241000234479 Narcissus Species 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 206010036631 Presenile dementia Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000002329 esterase inhibitor Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000008571 general function Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000005053 phenanthridines Chemical class 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200310115720 CN1270717C (en) | 2003-11-28 | 2003-11-28 | Galantamin sustained release preparation and preparing process |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200310115720 CN1270717C (en) | 2003-11-28 | 2003-11-28 | Galantamin sustained release preparation and preparing process |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1543959A true CN1543959A (en) | 2004-11-10 |
CN1270717C CN1270717C (en) | 2006-08-23 |
Family
ID=34337380
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200310115720 Expired - Lifetime CN1270717C (en) | 2003-11-28 | 2003-11-28 | Galantamin sustained release preparation and preparing process |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1270717C (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005099674A1 (en) * | 2004-04-14 | 2005-10-27 | Vectura Limited | Pharmaceutical compositions comprising an amphiphilic starch |
CN101090737B (en) * | 2004-12-27 | 2010-09-08 | 卫材R&D管理有限公司 | Method for stabilizing dementia-resisting medicine |
CN101829068A (en) * | 2010-05-06 | 2010-09-15 | 徐州市光合生物营养品有限公司 | Water soluble medicament sustained-release tablets and preparation method thereof |
CN101947205A (en) * | 2010-07-21 | 2011-01-19 | 河南中帅医药科技发展有限公司 | Novel galanthamine sustained-release preparation and preparation method thereof |
CN104970445A (en) * | 2015-07-21 | 2015-10-14 | 中国烟草总公司广东省公司 | Controlled-release aerosol cigarette |
-
2003
- 2003-11-28 CN CN 200310115720 patent/CN1270717C/en not_active Expired - Lifetime
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005099674A1 (en) * | 2004-04-14 | 2005-10-27 | Vectura Limited | Pharmaceutical compositions comprising an amphiphilic starch |
CN101090737B (en) * | 2004-12-27 | 2010-09-08 | 卫材R&D管理有限公司 | Method for stabilizing dementia-resisting medicine |
CN101829068A (en) * | 2010-05-06 | 2010-09-15 | 徐州市光合生物营养品有限公司 | Water soluble medicament sustained-release tablets and preparation method thereof |
CN101947205A (en) * | 2010-07-21 | 2011-01-19 | 河南中帅医药科技发展有限公司 | Novel galanthamine sustained-release preparation and preparation method thereof |
CN101947205B (en) * | 2010-07-21 | 2013-11-27 | 河南中帅医药科技发展有限公司 | Novel galanthamine sustained-release preparation and preparation method thereof |
CN104970445A (en) * | 2015-07-21 | 2015-10-14 | 中国烟草总公司广东省公司 | Controlled-release aerosol cigarette |
CN104970445B (en) * | 2015-07-21 | 2017-11-07 | 中国烟草总公司广东省公司 | A kind of spacetabs type aerosol mouth cigarette |
Also Published As
Publication number | Publication date |
---|---|
CN1270717C (en) | 2006-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101073563B (en) | Chiral composition containing dextrothyroxine buprofenli and levomethadyl cysteliqin and its double slow-releasing tablet | |
CN107669687A (en) | 5 HT for body weight control2CThe modified release dosage form of activator | |
EP0274176B1 (en) | Sustained release capsule or tablet formulation | |
CA2563058C (en) | Supportive treatment of liver disease | |
JPH02209A (en) | Control release compound of carbidopa/levodopa | |
CN1270717C (en) | Galantamin sustained release preparation and preparing process | |
CN1454054A (en) | Treating smooth muscle hyperactivity with (R)-oxybutynin and (R)-desethyloxybutynin | |
CN104000789A (en) | Adefovir dipivoxil dispersible tablet and preparation method thereof | |
WO2010022580A1 (en) | Medical composition for treating hyperuricemia and the use thereof | |
CN101081217A (en) | Slow-release small pill prparation containing huperzine A and method for making same | |
WO2010022581A1 (en) | Medical composition for treating hyperuricemia and the use thereof | |
CN1247195C (en) | Silibinin oral disintegration tablet and its preparing method | |
CN1927301A (en) | Tongmai Jiangzhi dispersant tablet and method for making same | |
WO2004069246A1 (en) | Drug compositions comprising inhibitors of cholinesterase for treating senile dementia | |
EP2034986A2 (en) | High dose oral pharmaceutical compositions of artemether and lumefantrine | |
CN1254240C (en) | Silibinin meglumine salt oral disintegration tablet preparation and its preparing method | |
RU2367438C2 (en) | Controlled release trimetazidine matrix tablet | |
CN1623548A (en) | Galanthamine slow release preparation and its preparation method | |
CN1931140A (en) | Orally disintegrated galantamine hydrobromide tablet and its prepn process | |
CN101947205B (en) | Novel galanthamine sustained-release preparation and preparation method thereof | |
CN1430964A (en) | Extractive preparation containing total alkali of mulberry leaves and its preparing method | |
CN103432596B (en) | Method for researching abirritation mechanism of Chinese herbal medicinal ingredients of Xinhuang tablets | |
JPH07507280A (en) | (-)-Metriphonate-containing drugs | |
CN104042581B (en) | Oxycodone hydrochloride sustained-release preparation and preparation method thereof | |
CN101869708A (en) | Medicament composition containing calcium channel blockers and biguanide antidiabetic medicine and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: WU LIANG YE GROUP, YIBIN PHARMACEUTICAL CO.,LTD., Free format text: FORMER OWNER: LI SICHENG Effective date: 20080425 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20080425 Address after: No. 2, middle Changjiang Road, Sichuan, Yibin Patentee after: SICHUAN YIBIN WULIANGYE GROUP YIBIN PHARMACEUTICAL Co.,Ltd. Address before: Sichuan Province, Chengdu City People's Road 4 Jinyuan Fairview Park South 8-2B Patentee before: Li Sicheng |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 644104 Binjiang East Road, Sichuan, Yibin Province Industrial Zone, No. East Road, No. 1 Patentee after: China Pharmaceutical Group Yibin Pharmaceutical Co.,Ltd. Address before: 644002 Yibin Changjiang Road, Sichuan, No. 2 Patentee before: SICHUAN YIBIN WULIANGYE GROUP YIBIN PHARMACEUTICAL Co.,Ltd. |
|
CX01 | Expiry of patent term |
Granted publication date: 20060823 |
|
CX01 | Expiry of patent term |